The mechanistic understanding of MISP's role in ferroptosis requires further validation across different NSCLC subtypes and various cancer types as to whether MISP‐MST1/2 signaling axis represents a common mechanism in remodeling ferroptosis in cancers. The gene discussed is MISP; the disease is cancer.